Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood thinner save teens from deadly clots?

NCT ID NCT06628778

Prevention Sponsor: Johns Hopkins All Children's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the blood thinner enoxaparin can prevent dangerous blood clots in teens who are critically ill in the intensive care unit. About 800 high-risk teens will receive either enoxaparin or a placebo. The goal is to see if the drug reduces clots without causing serious bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Enoxaparin (a blood thinner)
What this could lead to
If it works, this could provide a proven way to prevent dangerous blood clots in hospitalized teens, reducing complications and saving lives.
What could go wrong
This is a first-of-its-kind trial in children, so results are uncertain. Enoxaparin also raises bleeding risk, which must be carefully balanced against any benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 802 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2027

An estimate. Start dates often move.

Expected to finish

Apr 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Admission Age between 12- 18 years of age * Within 24 hours of pediatric intensive care unit (PICU) admission for enrollment * Presence of a Central Venous Catheter * Presumed or confirmed infection or systemic inflammatory condition Exclusion Criteria: * Active treatment for VTE or known VTE present prior to or on pediatric intensive care unit (PICU) admission * Current receipt of an antithrombotic agent excluding unfractionated heparin for vascular catheter patency * Active ISTH-defined clinically relevant bleeding * Surgery in the last 7-days * Major trauma within the last 7-days * Admission for management of congenital heart disease including perioperative management of critical congenital heart disease * Presence of coagulopathy including: * International normalized ratio (INR) 2.0 activated partial thromboplastin time (aPTT) 50 seconds Platelet count 50 x103/mL * Creatinine clearance 30 ml/min/1.73 m2 * Known hypersensitivity to heparin or pork products * Laboratory confirmed heparin induced thrombocytopenia * Current pregnancy or lactation, * Presence of an epidural catheter * Prior enrollment in the CRITICAL-Teens-TP Trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous thromboembolism (VTE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Critical Illness venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thromboembolism (VTE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Johns Hopkins All Children"s Hospital

    St. Petersburg, Florida, 33704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.